CRISPR Therapeutics AG (CRSP) Non-cash Items (2015 - 2026)

CRISPR Therapeutics AG has disclosed Non-cash Items across 12 years of filings, most recently posting $72.3 million for Q1 2026.

• Non-cash Items for Q1 2026 came in at $72.3 million, up 1334.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $72.3 million (up 1334.74% YoY), and the FY2025 annual result was $4.7 million, down 66.48% from the prior year.
• Non-cash Items came in at $72.3 million for Q1 2026 at CRISPR Therapeutics AG, up from $4.7 million in the prior quarter.
• In the past five years, Non-cash Items ranged from a high of $142.7 million in Q2 2022 to a low of $4.5 million in Q1 2024.
• The 5-year median for Non-cash Items is $5.0 million (2025), against an average of $44.7 million.
• Peak annual rise in Non-cash Items reached 3345.34% in 2022, while the deepest fall reached 97.51% in 2022.
• CRISPR Therapeutics AG's Non-cash Items stood at $32.1 million in 2022, then surged by 260.03% to $115.7 million in 2023, then slumped by 87.85% to $14.0 million in 2024, then sank by 66.48% to $4.7 million in 2025, then soared by 1435.2% to $72.3 million in 2026.
• The last three Non-cash Items figures came in at $72.3 million (Q1 2026), $4.7 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.